Trials / Completed
CompletedNCT05200013
BAT7104 in Patients With Advanced Solid Tumours
A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Bio-Thera Solutions · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective multi-centre, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients with Advanced Solid Tumours in Australia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BAT7104 | Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage |
Timeline
- Start date
- 2022-04-29
- Primary completion
- 2024-06-25
- Completion
- 2024-06-25
- First posted
- 2022-01-20
- Last updated
- 2024-10-18
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05200013. Inclusion in this directory is not an endorsement.